Table 2. Univariable and multivariable analysis of late intrahepatic recurrence-free survival and baseline characteristics.
| Factors | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (continuous) | 1.02 (1.01–1.03) | < 0.001 | 1.02 (1.01–1.03) | < 0.001 |
| Sex (male) | 1.22 (1.03–1.45) | 0.02 | 1.37 (1.14–1.64) | 0.001 |
| Diabetes (yes) | 1.31 (1.10–1.56) | 0.002 | 1.08 (0.90–1.29) | 0.42 |
| Hypertension (yes) | 1.12 (0.96–1.30) | 0.16 | - | - |
| Etiology (HCV vs. HBV) | 1.76 (1.35–2.31) | < 0.001 | 1.21 (0.90–1.63) | 0.30 |
| Etiology (alcohol/others vs. HBV) | 1.08 (0.85–1.37) | 0.99 | - | - |
| Liver cirrhosis (yes) | 1.60 (1.40–1.85) | < 0.001 | 1.30 (1.11–1.52) | 0.001 |
| Initial treatment (LAT vs. SR) | 1.98 (1.73–2.28) | < 0.001 | 1.52 (1.30–1.77) | < 0.001 |
| Edmonson grade (2 vs. 1) | 0.70 (0.41–1.22) | 0.37 | - | - |
| Edmonson grade (3 vs. 1) | 0.58 (0.31–1.08) | 0.11 | - | - |
| Edmonson grade (4 vs. 1) | 0.4 (0.07–2.37) | 0.66 | - | - |
| Microvascular invasion (yes) | 0.97 (0.8–1.19) | 0.79 | - | - |
| Bile duct invasion (yes) | 0.35 (0.09–1.40) | 0.14 | - | - |
| mALBI grade (2a vs. 1) | 1.73 (1.42–2.10) | < 0.001 | 1.50 (1.19–1.89) | < 0.001 |
| mALBI grade (2b/3 vs. 1) | 1.61 (1.34–1.94) | < 0.001 | 1.35 (1.05–1.74) | 0.01 |
| AFP (continuous) | 1.00 (1.00–1.00) | 0.08 | 1.00 (1.00–1.00) | 0.36 |
| PIVKA-II (continuous) | 1.00 (1.00–1.00) | 0.2 | - | - |
| Number of tumors (2–3 vs. 1) | 1.57 (1.24–1.97) | < 0.001 | 1.23 (0.97–1.56) | 0.08 |
| Tumor size (continuous) | 0.90 (0.86–0.95) | 0.18 | - | - |
| BCLC stage (A) | 0.98 (0.85–1.12) | 0.73 | - | - |
| ANC (continuous) | 1.00 (1.00–1.00) | < 0.001 | 1.00 (1.00–1.00) | 0.63 |
| ALC (continuous) | 1.00 (1.00–1.00) | 0.11 | - | - |
| AMC (continuous) | 1.00 (1.00–1.00) | 0.27 | - | - |
| NLR (continuous) | 0.93 (0.88–0.99) | 0.03 | 0.99 (0.89–1.09) | 0.80 |
| PLR (continuous) | 0.99 (0.99–1.00) | < 0.001 | 1.00 (0.99–1.00) | 0.03 |
| LMR (continuous) | 0.95 (0.92–0.99) | 0.009 | 0.96 (0.92–1.00) | 0.06 |
| SII (continuous) | 1.00 (1.00–1.00) | < 0.001 | - | - |
| APRI (continuous) | 1.15 (1.10–1.20) | 0.009 | 1.10 (0.98–1.27) | 0.16 |
| ALRI (continuous) | 1.00 (1.00–1.00) | 0.01 | 1.00 (0.99–1.00) | 0.22 |
HR = hazard ratio, CI = confidence interval, HCV = hepatitis C virus, HBV = hepatitis B virus, LAT = local ablation therapy, SR = surgical resection, mALBI = modified albumin-bilirubin, AFP = α-fetoprotein, PIVKA-II = protein induced by vitamin K antagonist-II, BCLC = Barcelona Clinic Liver Cancer, ANC = absolute neutrophil count, ALC = absolute lymphocyte count, AMC = absolute monocyte count, NLR = neutrophil-to-lymphocyte ratio, PLR = platelet-to-lymphocyte ratio, LMR = lymphocyte-to-monocyte ratio, SII = systemic immune-inflammation index, APRI = aspartate aminotransferase-to-platelet ratio, ALRI = aspartate aminotransferase-to-lymphocyte ratio.